Daiwa Securities Group Inc. Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Daiwa Securities Group Inc. raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 32.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,590 shares of the company’s stock after acquiring an additional 2,109 shares during the period. Daiwa Securities Group Inc.’s holdings in Neurocrine Biosciences were worth $1,185,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Fidelis Capital Partners LLC purchased a new stake in shares of Neurocrine Biosciences in the first quarter worth about $99,000. Tokio Marine Asset Management Co. Ltd. increased its stake in Neurocrine Biosciences by 23.2% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,755 shares of the company’s stock worth $518,000 after acquiring an additional 707 shares during the last quarter. Capstone Investment Advisors LLC raised its holdings in shares of Neurocrine Biosciences by 136.1% during the 1st quarter. Capstone Investment Advisors LLC now owns 5,652 shares of the company’s stock worth $780,000 after acquiring an additional 3,258 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Neurocrine Biosciences by 3.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 8,907 shares of the company’s stock valued at $1,228,000 after acquiring an additional 270 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Neurocrine Biosciences by 40.4% in the first quarter. BNP Paribas Financial Markets now owns 431,982 shares of the company’s stock valued at $59,579,000 after purchasing an additional 124,352 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In related news, Director Stephen A. Sherwin sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the sale, the director now owns 26,504 shares in the company, valued at $3,537,223.84. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Neurocrine Biosciences news, insider Eric Benevich sold 19,818 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the transaction, the insider now owns 40,778 shares in the company, valued at $5,438,154.08. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Stephen A. Sherwin sold 40,000 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the transaction, the director now owns 26,504 shares in the company, valued at approximately $3,537,223.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,697 shares of company stock worth $13,377,515. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the topic of a number of recent research reports. Barclays upped their price objective on Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a research report on Thursday, May 2nd. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, May 1st. StockNews.com downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, June 21st. Citigroup increased their price objective on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, Evercore ISI began coverage on Neurocrine Biosciences in a research note on Tuesday, May 14th. They set an “outperform” rating and a $175.00 target price on the stock. Six research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $152.58.

View Our Latest Stock Report on Neurocrine Biosciences

Neurocrine Biosciences Stock Up 2.7 %

Shares of NBIX opened at $147.12 on Thursday. The company has a 50 day moving average of $137.74 and a two-hundred day moving average of $136.76. The company has a market cap of $14.81 billion, a price-to-earnings ratio of 40.53 and a beta of 0.37. Neurocrine Biosciences, Inc. has a twelve month low of $94.16 and a twelve month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last announced its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). The business had revenue of $515.30 million for the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.22 EPS for the current year.

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

See Also

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.